Sigyn Therapeutics, Inc. (SIGY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sigyn Therapeutics, Inc. (SIGY) trades at $0.03. Sigyn Therapeutics, Inc. is a development-stage therapeutic technology company focused on blood purification to treat inflammatory disorders. Their Sigyn Therapy aims to address limitations of existing treatments for conditions like sepsis. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SIGY: SIGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SIGY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SIGY.
How is this calculated? →Sigyn Therapeutics, Inc. (SIGY) Healthcare & Pipeline Overview
Sigyn Therapeutics, Inc., a development-stage biotech firm, is focused on pioneering blood purification technology, Sigyn Therapy, to combat life-threatening inflammatory disorders such as sepsis. The company aims to address the limitations of existing treatments by targeting a broad spectrum of inflammatory mediators.
What Is the Investment Thesis for SIGY?
Sigyn Therapeutics presents a high-risk, high-reward investment opportunity, typical of development-stage biotechnology companies. The core value driver is the potential of Sigyn Therapy to address unmet needs in treating life-threatening inflammatory disorders, particularly sepsis. Successful preclinical and clinical trials demonstrating the efficacy and safety of Sigyn Therapy would serve as major catalysts. The company's small size and OTC listing introduce liquidity and regulatory risks. Investors should closely monitor the company's progress in securing funding, advancing its technology through clinical trials, and navigating the regulatory landscape. The negative profit margin of -55785.8% reflects the company's development stage.
Based on FMP financials and quantitative analysis
SIGY Key Highlights
Sigyn Therapy is a blood purification technology targeting a broad spectrum of inflammatory mediators.
- The company is focused on addressing the limitations of existing treatments for life-threatening inflammatory disorders, including sepsis.
- Sigyn Therapeutics operates as a development-stage company, indicating a high-risk, high-reward investment profile.
- The company's gross margin is 26.4%.
- The company has a negative P/E ratio of -0.03, reflecting its current lack of profitability.
Who Are SIGY's Competitors?
SIGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +5.06% | $7.16M | 72 |
| RLYB Rallybio Corporation | $17.00 | +1.37% | $90.2M | 81 |
| ICCC ImmuCell Corporation | $10.13 | +3.79% | $91.6M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.44 | +2.52% | $231M | 76 |
| NAGE Niagen Bioscience Inc | $3.17 | +3.59% | $252M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SIGY's Key Strengths?
Novel blood purification technology.
- Potential to address unmet needs in sepsis treatment.
- Broad-spectrum targeting of inflammatory mediators.
What Are SIGY's Weaknesses?
Development-stage company with limited resources.
- Reliance on successful clinical trials and regulatory approval.
- OTC listing and associated risks.
What Could Drive SIGY Stock Higher?
Initiation of Phase 1 clinical trials for Sigyn Therapy in sepsis patients.
- Publication of preclinical data demonstrating the efficacy of Sigyn Therapy against viral pathogens.
- Ongoing research and development efforts to expand the applications of Sigyn Therapy.
- Securing additional funding through grants, partnerships, or private placements.
What Are the Key Risks for SIGY?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial results or safety concerns.
- Regulatory delays or rejection of Sigyn Therapy.
- Competition from established pharmaceutical and medical device companies.
- Limited financial resources and dependence on external funding.
- Risks associated with OTC listing, including low liquidity and potential for price manipulation.
What Are the Growth Opportunities for SIGY?
- Expansion into Sepsis Treatment: Sepsis represents a significant market opportunity for Sigyn Therapy. Successful clinical trials demonstrating the efficacy of Sigyn Therapy in reducing mortality and improving outcomes in sepsis patients could lead to rapid adoption and market penetration. The timeline for this growth opportunity depends on the successful completion of clinical trials, which could take several years.
- Application in Viral Infections: Sigyn Therapy's potential to remove viral pathogens from the blood offers a growth opportunity in the treatment of severe viral infections. As new viral threats emerge, the demand for effective therapies to combat viral sepsis and other complications will increase. The timeline for this growth opportunity depends on research and development efforts to validate the efficacy of Sigyn Therapy against specific viral pathogens.
- Treatment of Hepatic Disorders: The ability of Sigyn Therapy to remove hepatic toxins presents a growth opportunity in the treatment of liver failure and other hepatic disorders. The market for liver disease therapies is growing, driven by the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and other liver conditions. Clinical trials demonstrating the efficacy of Sigyn Therapy in improving liver function and reducing complications could lead to adoption in this market segment. The timeline for this growth opportunity depends on the successful completion of clinical trials.
- Addressing Cytokine Storms: Sigyn Therapy's potential to remove pro-inflammatory cytokines, such as TNF-alpha, IL-1 beta, and IL-6, positions it as a potential treatment for cytokine storms associated with various inflammatory conditions, including autoimmune diseases and cancer immunotherapy. The market for cytokine storm therapies is growing, driven by the increasing use of immunotherapies and the need for effective treatments to manage their side effects. The timeline for this growth opportunity depends on research and development efforts to validate the efficacy of Sigyn Therapy in managing cytokine storms.
- Partnerships and Licensing Agreements: Sigyn Therapeutics can pursue growth through strategic partnerships and licensing agreements with larger pharmaceutical or medical device companies. These collaborations can provide access to funding, expertise, and distribution channels, accelerating the development and commercialization of Sigyn Therapy. The timeline for this growth opportunity depends on the company's ability to secure favorable partnership agreements, which can be influenced by clinical trial results and market demand.
What Are SIGY's Competitive Advantages?
- Proprietary Sigyn Therapy technology.
- Potential for broad-spectrum treatment of inflammatory mediators.
- Focus on addressing unmet needs in sepsis treatment.
What Does SIGY Do?
Sigyn Therapeutics, Inc., headquartered in San Diego, California, is a development-stage therapeutic technology company dedicated to revolutionizing the treatment of life-threatening inflammatory disorders. The company's core technology, Sigyn Therapy, is a blood purification system designed to overcome the limitations of conventional drugs and devices in addressing conditions like sepsis, a leading cause of hospital deaths. Sigyn Therapy is being evaluated for its potential to target a wide range of inflammatory mediators, including endotoxin, peptidoglycan, lipoteichoic acid, viral pathogens, hepatic toxins, CytoVesicles, and pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. Founded with the mission to innovate in the treatment of inflammatory diseases, Sigyn Therapeutics is focused on advancing Sigyn Therapy through preclinical and clinical development. The company's approach involves a broad-spectrum blood purification strategy, aiming to remove multiple disease-causing agents simultaneously. This contrasts with traditional therapies that often target a single mediator or pathogen. As a development-stage company, Sigyn Therapeutics is actively engaged in research and development efforts to validate the efficacy and safety of Sigyn Therapy across various therapeutic targets.
What Products and Services Does SIGY Offer?
- Develops blood purification technology.
- Offers Sigyn Therapy for inflammatory disorders.
- Targets sepsis and related conditions.
- Removes endotoxins and other inflammatory mediators.
- Evaluates applications for viral pathogens.
- Investigates treatment of hepatic toxins.
- Addresses pro-inflammatory cytokines.
How Does SIGY Make Money?
- Focuses on research and development of Sigyn Therapy.
- Seeks to commercialize Sigyn Therapy through regulatory approval.
- Aims to generate revenue through product sales or licensing agreements.
What Industry Does SIGY Operate In?
Sigyn Therapeutics operates within the biotechnology industry, specifically focusing on blood purification technologies for inflammatory disorders. The market for sepsis treatment is substantial, driven by the high mortality rate and limited efficacy of current therapies. The competitive landscape includes companies developing targeted therapies for specific inflammatory mediators, as well as those focused on broader immune modulation approaches. Sigyn Therapeutics aims to differentiate itself through its broad-spectrum blood purification technology, potentially offering a more comprehensive solution for complex inflammatory conditions. The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful products.
Who Are SIGY's Key Customers?
- Hospitals and intensive care units.
- Patients with sepsis and other inflammatory disorders.
- Healthcare providers treating severe infections.
Company Profile
Sigyn Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO James A. Joyce. SIGY has traded publicly since 2021.
Key Financial Metrics
Return on equity for Sigyn Therapeutics, Inc. stands at 57.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Sigyn Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Sigyn Therapeutics, Inc. revenue of about $2.0M for fiscal 2026, with EPS near $-420.00.
SIGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel blood purification technology.
- Potential to address unmet needs in sepsis treatment.
- Broad-spectrum targeting of inflammatory mediators.
- Upcoming: Initiation of Phase 1 clinical trials for Sigyn Therapy in sepsis patients.
Bear Case
- Development-stage company with limited resources.
- Reliance on successful clinical trials and regulatory approval.
- OTC listing and associated risks.
- Potential: Unsuccessful clinical trial results or safety concerns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SIGY Latest News
No recent news available for SIGY.
SIGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SIGY.
Price Targets
Wall Street price target analysis for SIGY.
SIGY MoonshotScore
What does this score mean?
The MoonshotScore rates SIGY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James A. Joyce
CEO
James A. Joyce serves as the CEO of Sigyn Therapeutics, Inc. His background includes experience in managing small teams and leading development-stage companies. He is responsible for overseeing the company's strategic direction, research and development efforts, and fundraising activities. His leadership is crucial for guiding Sigyn Therapeutics through the challenges of clinical trials and regulatory approval processes.
Track Record: Under James A. Joyce's leadership, Sigyn Therapeutics has focused on advancing Sigyn Therapy through preclinical development and preparing for clinical trials. Key milestones include securing funding for research and development, establishing partnerships with research institutions, and obtaining regulatory clearances for clinical trials. His focus is on validating the efficacy and safety of Sigyn Therapy.
SIGY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sigyn Therapeutics may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting, potentially increasing the risk for investors. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies often have less stringent listing standards, resulting in greater volatility and risk. This tier is often populated by shell companies, defunct companies, or companies with questionable operations.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and high volatility.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Focus on developing a novel therapeutic technology.
- Engagement with research institutions and key opinion leaders.
- Efforts to secure regulatory clearances for clinical trials.
Common Questions About SIGY (Healthcare)
What does Sigyn Therapeutics, Inc. do?
Sigyn Therapeutics, Inc. is a development-stage biotechnology company focused on creating and commercializing Sigyn Therapy, a blood purification technology designed to treat life-threatening inflammatory disorders. Their primary focus is on sepsis, a condition with high mortality rates and limited effective treatments.
What do analysts say about SIGY stock?
As of March 17, 2026, there is no readily available analyst coverage for Sigyn Therapeutics (SIGY) due to its OTC listing and development-stage nature. Key valuation metrics, such as price-to-earnings ratio and revenue multiples, are not applicable at this stage.
What are the main risks for SIGY?
Sigyn Therapeutics faces several key risks inherent to development-stage biotechnology companies, including the potential for unsuccessful clinical trial results, regulatory delays or rejection, and competition from established players. The company's limited financial resources and dependence on external funding also pose a significant risk. Furthermore, its OTC listing introduces additional risks related to low liquidity, price volatility, and potential for manipulation. Investors should carefully consider these risks before investing in SIGY.
What are the key factors to evaluate for SIGY?
Evaluate SIGY on fundamentals, analyst consensus, and risk factors. Sigyn Therapeutics presents a high-risk, high-reward investment opportunity, typical of development-stage biotechnology companies. Not financial advice.
How frequently does SIGY data refresh on this page?
SIGY's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SIGY's recent stock price performance?
Sigyn Therapeutics, Inc. (SIGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel blood purification technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SIGY overvalued or undervalued right now?
Sigyn Therapeutics, Inc. (SIGY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SIGY before investing?
Before investing in Sigyn Therapeutics, Inc. (SIGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data for this OTC-listed company.
- AI analysis pending may provide further insights in the future.